Effect of Desflurane Versus Sevoflurane With Recent Bio-markers on Renal and Hepatic Functions

Theodor Bilharz Research Institute

Status: Completed

Conditions: Postoperative Complications

Treatments: Drug: Sevoflurane; Drug: Desflurane; Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Study type: Observational

Funder types: Other

Identifiers

NCT05027191

110-T

Details and patient eligibility

About

Studying the effects of both inhalational anesthetics desflurane and sevoflurane on hepatic integrity and renal function, guided by recent blood and urine biomarkers in patients undergoing laparoscopic cholecystectomy surgery.

Enrollment: 70 patients

Sex: All

Ages: 25 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. American Society of Anesthesiologists (ASA) Class: I&II.
2. Elective laparoscopic cholecystectomy.
3. Age: 25-55 years.
4. Gender: Both male and female.
5. Body Mass Index (BMI): 18.5-24.9 km2-(Normal weight).

Exclusion criteria

1. Extremes of age.
2. Abnormal hepatic function by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values outside the normal range.
3. Abnormal renal function by blood urea nitrogen (BUN) and creatinine above the normal ranges.
4. Hypertension, unstable angina pectoris or myocardial infarction within the last six months.
5. Pregnancy and lactation.
6. Bronchial asthma.
7. Drug allergies.
8. Alcohol or drug addiction.
9. General anesthesia within the last three months.

Trial design

70 participants in 2 patient groups

Sevoflurane

Description:

This group will receive sevoflurane as the maintenance inhalational anesthetic.

Treatment:

Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Drug: Sevoflurane

Desflurane

Description:

This group will receive desflurane as the maintenance inhalational anesthetic.

Treatment:

Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL)

Drug: Desflurane